Changes of matrix metalloproteinase-9 and its tissue inhibitor (TIMP-1) after autologous hematopoietic stem cell transplantation in multiple sclerosis

J Neuroimmunol. 2004 Aug;153(1-2):190-4. doi: 10.1016/j.jneuroim.2004.05.005.

Abstract

Elevated levels of matrix metalloproteinase-9 (MMP-9) associates with predictors of multiple sclerosis (MS) activity. We analysed serum levels and mRNA expression of MMP-9 and its inhibitor TIMP-1 in peripheral mononuclear cells of 14 MS patients after autologous hematopoietic stem cell transplantation (AHSCT). All but 2 patients stabilized after AHSCT. A significant decrease of MMP-9 levels was seen up to 36 months after AHSCT. TIMP-1 levels did not change. MMP-9 mRNA levels correlated with the CD4+ T cell count (p<0.0001). The significant and persistent change in MMP-9 activity after AHSCT may be caused in part by the effect of AHSCT in the CD4+ T cell count.

Publication types

  • Comparative Study

MeSH terms

  • Follow-Up Studies
  • Hematopoietic Stem Cell Transplantation / methods*
  • Humans
  • Matrix Metalloproteinase 9 / genetics
  • Matrix Metalloproteinase 9 / metabolism*
  • Multiple Sclerosis / enzymology
  • Multiple Sclerosis / metabolism
  • Multiple Sclerosis / therapy*
  • RNA, Messenger / metabolism
  • Statistics, Nonparametric
  • Time Factors
  • Tissue Inhibitor of Metalloproteinase-1 / genetics
  • Tissue Inhibitor of Metalloproteinase-1 / metabolism*
  • Transplantation, Autologous / methods*

Substances

  • RNA, Messenger
  • Tissue Inhibitor of Metalloproteinase-1
  • Matrix Metalloproteinase 9